B
lood platelets and oxidized low-density lipoprotein (oxLDL) are critically involved in atherogenesis and acute coronary syndromes (ACS). [1] [2] [3] [4] [5] [6] Although their interplay in platelet activation, foam cell formation, and vascular inflammation has been suggested by several experimental studies, [4] [5] [6] [7] its clinical value remains obscure. oxLDL binds to 5 scavenger receptors expressed on the platelet surface: class A scavenger receptor, CD36, lectin-like oxidized LDL receptor-1, class B scavenger receptor I, and scavenger receptor that binds phosphatidylserine and oxidized lipoprotein/chemokine (C-X-C motif) ligand 16. 5, 6 We have previously reported that binding of oxLDL on platelets results in enhanced platelet activation and platelet phagocytosis by macrophages and foam cell formation. 4, 6, 7 Therefore, platelet-oxLDL interaction may play a crucial role in the initiation and progression of arteriosclerosis, but its clinical relevance has not been elucidated so far. The aim of the present study was to assess platelet-bound oxLDL in patients with stable coronary artery disease (CAD) or ACS and its association with clinical presentation of CAD and platelet activation. Furthermore, the impact of oxLDL on platelet adhesion to the vascular wall in vitro and in vivo was investigated.
Patients and Methods
Detailed description of patients, methods, and materials is presented in the online-only Data Supplement.
Patients
Three hundred fifty-six consecutive patients with symptomatic CAD undergoing coronary angiography were recruited into the study.
Informed written consent was obtained from each patient, and the study was approved by the local ethics committee.
Whole-Blood Flow Cytometry
Whole blood obtained from all patients was studied for plateletbound oxLDL and glycoprotein Ib (GPIb) (CD42b) by flow cytometry analysis. The surface expression of P-selectin (CD62P) and activated fibrinogen receptor (GPIIb/IIIa) was measured as markers of platelet activation.
Adhesion Assays In Vitro
To evaluate platelet adhesion of human platelets from healthy donors to immobilized collagen or endothelial cells under flow conditions, perfusion experiments were performed at shear rates of 2000 per second (high shear) in a flow chamber (Oligene, Berlin, Germany).
Intravital Microscopy
The common carotid artery of C57BL/6J mice or apolipoprotein E −/− mice fed a high cholesterol diet for 6 weeks was dissected free and ligated vigorously for 5 minutes to induce vascular injury. Before and after vascular injury, platelet-endothelium interaction was visualized by in vivo video microscopy. All images were recorded and evaluated off-line.
Statistical Analysis
Data are presented as mean±SD, unless otherwise stated. All tests were 2-tailed, and statistical significance was considered for P<0.05. All statistical analyses were performed using SPSS version 19 for windows (Chicago, IL).
Results
We first analyzed the surface expression of platelet-bound oxLDL in a consecutive cohort of 356 patients with symptomatic CAD, including ACS (n=174) and stable angina pectoris (SAP; n=182) as well as in an elderly group of patients without known or suspected CAD (n=30). The demographic details are given in Table I 144; P=0.024) . In a univariate ANOVA, the increase of platelet-bound oxLDL in ACS was influenced only by high-density lipoprotein levels and number of coronary arteries affected (Table) .
In vitro, isolated human platelets from healthy donors treated with oxLDL showed increased activation as assessed by the expression of P-selectin and activated GPIIb/IIIa ( Figure Figure) . Interestingly, adhesion of oxLDL-treated platelets to endothelial cells was inhibited by preincubation with an anti-GPIIb/IIIa antibody, but not with an anti-GPIbα antibody, whereas adhesion to immobilized collagen was significantly reduced by soluble GPVI-Fc compared with Fc control ( Figure VI in the online-only Data Supplement). In vivo, platelet adhesion to the injured vascular wall after carotid ligation in C57BL/6J mice was significantly increased after treatment of platelets with human oxLDL compared with LDL (Figure) . Accordingly, we performed intravital microscopy experiments in atherosclerotic apolipoprotein E −/− mice fed a high cholesterol diet and observed increased adhesion of oxLDL-treated platelets to the vascular lesion compared with LDL-treated platelets (P<0.05; Figure  VII in the online-only Data Supplement).
Discussion
The major findings of the present study are as follows: (1) binding of oxLDL on circulating platelets is elevated in patients with ACS compared with patients with stable CAD; (2) oxLDL binding on the platelet surface correlates with platelet activation; (3) binding of oxLDL, but not of native LDL, on isolated platelets results in enhanced platelet adhesion to immobilized collagen and activated cultured endothelium in vitro and to the injured carotid artery in vivo.
oxLDL plays a key role in CAD and, particularly, in ACS by increasing the vulnerability of coronary atherosclerotic plaques. 2, 8 OxLDL induces macrophage activation, foam cell generation, smooth muscle cell proliferation, and a decrease in endothelial production of NO. Furthermore, oxLDL promotes thrombogenicity by stimulating the release of tissue factor but, most importantly, by enhancing platelet activation and adhesion to endothelium. Platelet exposure to oxLDL varies depending on the available concentrations of oxLDL either in blood (circulating oxLDL) or at sites of unstable lesions where increased oxLDL concentrations are released after plaque rupture. 9 In vitro studies have shown that oxLDL binds to platelet CD36, inducing platelet activation. 10 In the present study, we show for the first time that oxLDL binding to platelets is increased in ACS and correlates with the extent of platelet activation in patients with CAD. In conclusion, lipid oxidation may represent the link between dyslipidemia and prothrombotic state. Interactions between oxLDL and platelets enhance platelet reactivity and adhesion and may play a crucial role in coronary thrombosis in ACS. Lipoprotein-platelet interplay may be a promising therapeutic target in patients with atherothrombotic disease.
